Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|21|27|3173-3187

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.27, 2014-09, pp. : 3173-3187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer

By  

Current Cancer Drug Targets, Vol. 7, Iss. 6, 2007-09 ,pp. : 591-604

Bentham Science Publishers

Access to resources Recommend Favorite

New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway

By  

Current Pharmaceutical Design, Vol. 12, Iss. 3, 2006-01 ,pp. : 327-340

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside

By  

Current Medicinal Chemistry, Vol. 14, Iss. 19, 2007-08 ,pp. : 2009-2023

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells

By  

Current Medicinal Chemistry, Vol. 18, Iss. 18, 2011-06 ,pp. : 2715-2726

Bentham Science Publishers

Access to resources Recommend Favorite

Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?

By Fujino H.   Regan J.W.  

Trends in Pharmacological Sciences, Vol. 24, Iss. 7, 2003-07 ,pp. : 335-340

Elsevier

Access to resources Recommend Favorite